{"id":"https://openalex.org/W2129146015","doi":null,"title":"Phase I trial of temozolomide using an extended continuous oral schedule.","display_name":"Phase I trial of temozolomide using an extended continuous oral schedule.","publication_year":1998,"publication_date":"1998-10-01","ids":{"openalex":"https://openalex.org/W2129146015","mag":"2129146015","pmid":"https://pubmed.ncbi.nlm.nih.gov/9766665"},"language":"en","primary_location":{"id":"pmid:9766665","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9766665","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058165795","display_name":"C. Brock","orcid":"https://orcid.org/0000-0002-5893-7942","observed_orcids":["https://orcid.org/0000-0002-5893-7942"]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C S Brock","raw_affiliation_strings":["Medical Oncology Unit, Charing Cross Hospital, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Unit, Charing Cross Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I2802369498"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108452347","display_name":"Edward S. Newlands","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E S Newlands","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058765817","display_name":"Stephen R. Wedge","orcid":"https://orcid.org/0000-0002-3644-6157","observed_orcids":["https://orcid.org/0000-0002-3644-6157"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S R Wedge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063643387","display_name":"Mark Bower","orcid":"https://orcid.org/0000-0002-4077-6351","observed_orcids":["https://orcid.org/0000-0002-4077-6351"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Bower","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063821529","display_name":"Helen S Evans","orcid":"https://orcid.org/0000-0001-9129-083X","observed_orcids":["https://orcid.org/0000-0001-9129-083X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H Evans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058160709","display_name":"Iain R. Colquhoun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I Colquhoun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"M Roddie","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Roddie","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041038669","display_name":"Mark G. Glaser","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Glaser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108074722","display_name":"MH Brampton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M H Brampton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5047753094","display_name":"Gordon J.S. Rustin","orcid":"https://orcid.org/0000-0002-2749-5467","observed_orcids":["https://orcid.org/0000-0002-2749-5467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G J Rustin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.8113,"has_fulltext":false,"cited_by_count":280,"citation_normalized_percentile":{"value":0.95555262,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":90,"max":99},"biblio":{"volume":"58","issue":"19","first_page":"4363","last_page":"7"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8669999837875366},{"id":"https://openalex.org/keywords/plasma-pharmacokinetics","display_name":"plasma pharmacokinetics","score":0.8880000114440918},{"id":"https://openalex.org/keywords/glioma","display_name":"glioma","score":0.8209999799728394},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8259999752044678},{"id":"https://openalex.org/keywords/mycosis-fungoides","display_name":"mycosis fungoides","score":0.9419999718666077},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9490000009536743},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6150000095367432},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.6349999904632568},{"id":"https://openalex.org/keywords/refractory-disease","display_name":"refractory disease","score":0.4580000042915344},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.5669999718666077},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.3409999907016754},{"id":"https://openalex.org/keywords/oral-chemotherapy","display_name":"oral chemotherapy","score":0.3230000138282776},{"id":"https://openalex.org/keywords/nausea-and-vomiting","display_name":"nausea and vomiting","score":0.6349999904632568},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.9219855070114136},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.881062388420105},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6375206112861633},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6293424367904663},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5904074907302856},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5493197441101074},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4668140411376953},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4632142186164856},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.4489341676235199},{"id":"https://openalex.org/C2779051857","wikidata":"https://www.wikidata.org/wiki/Q911386","display_name":"Stomatitis","level":2,"score":0.43355563282966614},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.400881290435791},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3993760049343109},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3633289337158203},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3424184024333954}],"mesh":[{"descriptor_ui":"D000077204","descriptor_name":"Temozolomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002138","descriptor_name":"Calibration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004739","descriptor_name":"England","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005910","descriptor_name":"Glioma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005910","descriptor_name":"Glioma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:9766665","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9766665","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Clinical Trial"},{"id":"mag:2129146015","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9766665","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W1481142464","https://openalex.org/W1835101589","https://openalex.org/W1973027090","https://openalex.org/W1993808515","https://openalex.org/W2006998103","https://openalex.org/W2030810232","https://openalex.org/W2076176285","https://openalex.org/W2079203845","https://openalex.org/W2079786467"],"related_works":["https://openalex.org/W2053155962","https://openalex.org/W2079786467","https://openalex.org/W2020310916","https://openalex.org/W1575812451","https://openalex.org/W2105065380","https://openalex.org/W2070932441","https://openalex.org/W1698181436","https://openalex.org/W1997349871","https://openalex.org/W1973027090","https://openalex.org/W160130632"],"abstract_inverted_index":{"Temozolomide,":[0],"a":[1,19,41,47,306,332,374,378,407],"methylating":[2],"imidazotetrazinone,":[3],"has":[4],"antitumor":[5],"activity":[6],"against":[7],"gliomas,":[8],"malignant":[9,245],"melanoma,":[10],"and":[11,14,60,94,98,164,176,195,198,201,206,218,248,362,406],"mycosis":[12],"fungoides":[13],"is":[15,417],"presently":[16],"administered":[17,39,108],"as":[18,40],"5-day":[20,71,388],"oral":[21,43,297],"schedule":[22,265,346,389],"every":[23,394],"4":[24,121,204,244],"weeks.":[25],"This":[26],"Phase":[27],"I":[28],"study":[29],"aimed":[30],"to":[31,126,139],"determine":[32],"the":[33,54,69,135,143,178,181,345,351,360,366,387,418],"maximum":[34,334],"tolerated":[35,335,344],"dose":[36,45,124,329,336,342,421],"of":[37,80,180,184,211,221,243,250,271,277,282,313,321,337,365,370,390,425],"temozolomide":[38,217,290,322,352],"single":[42],"daily":[44],"for":[46,149,160,262,414,422],"continuous":[48],"6-":[49],"or":[50,103],"7-week":[51,375],"period,":[52],"evaluate":[53],"plasma":[55,63,169,289,301,319,353],"pharmacokinetics":[56,170],"on":[57,173],"this":[58,263,426],"schedule,":[59],"compare":[61],"total":[62],"exposure":[64],"over":[65,373],"7":[66,140,249,270,415],"weeks":[67,383,416],"with":[68,75,147,309,331,386],"conventional":[70],"regimen.":[72],"Twenty-four":[73],"patients":[74,213,223,237,247,253,285],"varying":[76],"tumor":[77,256],"types":[78],"(17":[79],"24":[81,272,278],"gliomas)":[82],"received":[83],"temozolomide.":[84,241],"All":[85],"had":[86],"clinically":[87],"evaluable,":[88],"refractory":[89],"disease;":[90],"normal":[91],"renal,":[92],"hepatic,":[93],"bone":[95],"marrow":[96],"function;":[97],"WHO":[99],"performance":[100],"status":[101],"<":[102],"=":[104,187],"2.":[105],"Temozolomide":[106,168,368,411],"was":[107,137,266,302,325,357,401],"at":[109,117,177],"50":[110],"mg/m2/day,":[111,128,339],"increasing":[112],"by":[113,305],"25":[114],"mg/m2/day/cohort":[115],"until":[116],"100":[118,215],"mg/m2/day":[119,134,216,240,372,392],"grade":[120,233],"myelotoxicity":[122],"forced":[123],"reductions":[125],"85":[127,225,338],"then":[129],"75":[130,133,239,371],"mg/m2/day.":[131,226],"At":[132],"regimen":[136],"extended":[138],"weeks,":[141],"allowing":[142],"future":[144],"potential":[145],"combination":[146],"irradiation":[148],"primary":[150],"gliomas.":[151],"Patient":[152],"responses":[153],"(standard":[154],"Union":[155],"International":[156],"Contre":[157],"Cancer":[158],"criteria;":[159],"gliomas":[161],"objective":[162],"response)":[163],"toxicity":[165],"were":[166,171,193,292],"assessed.":[167],"determined":[172],"day":[174],"1":[175,197,276],"beginning":[179],"final":[182],"week":[183,364],"administration":[185,369],"(n":[186],"5).":[188],"The":[189,258,348,397],"most":[190],"frequent":[191],"toxicities":[192,229],"myelosuppression":[194],"grades":[196],"2":[199,234],"nausea":[200],"vomiting.":[202],"Grade":[203],"leucopenia":[205],"thrombocytopenia":[207],"occurred":[208],"in":[209,219,235,300,327,384],"one":[210,220],"four":[212],"receiving":[214,224,238],"seven":[222],"These":[227],"hematological":[228],"did":[230],"not":[231],"exceed":[232],"10":[236],"One":[242],"melanoma":[246],"17":[251,283],"glioma":[252,284],"(41%)":[254],"demonstrated":[255],"responses.":[257],"overall":[259,398],"response":[260,399],"rate":[261,400],"prolonged":[264],"33%":[267,402],"(objective":[268],"response,":[269,275],"patients;":[273],"partial":[274],"patients);":[279],"also,":[280],"6":[281],"maintained":[286],"SD.":[287],"Peak":[288],"concentrations":[291],"obtained":[293],"30-90":[294],"min":[295],"after":[296],"administration.":[298],"Elimination":[299],"best":[303],"described":[304],"monoexponential":[307],"equation":[308],"an":[310],"elimination":[311],"half-life":[312],"96":[314],"+/-":[315],"16":[316],"min.":[317],"No":[318],"accumulation":[320],"occurred.":[323],"Toxicity":[324],"greatest":[326],"higher":[328],"cohorts,":[330],"resultant":[333],"whereas":[340],"lower":[341],"cohorts":[343],"well.":[347],"area":[349],"under":[350],"versus":[354],"time":[355],"curve":[356],"noncumulative":[358],"between":[359],"first":[361],"last":[363],"schedule.":[367,427],"period":[376],"permits":[377],"2.1-fold":[379],"greater":[380],"drug":[381],"exposure/4":[382],"comparison":[385],"200":[391],"repeated":[393],"28":[395],"days.":[396],"(glioma":[403],"patients,":[404],"41%":[405],"further":[408,423],"25%":[409],"SD).":[410],"(75":[412],"mg/m2/day)":[413],"recommended":[419],"starting":[420],"assessment":[424]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":11},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}